Bryan Gant

Representative cases include the following:

Representing a leading credit reporting agency in connection with antitrust claims based on its agreements with a supplier.

Representing a financial clearing firm in connection with antitrust claims based on the January 2021 "Short Squeeze."

Representing Pfizer in monopolization and restraint of trade cases involving allegations of unlawful "reverse payment" settlements as well as claims of fraud on the United States Patent and Trademark Office, including with respect to Lipitor, the best-selling drug of all time, and Effexor XR.

Represented Gilead, a leading manufacturer of HIV medications, in connection with allegations of unlawful agreements with joint venture partners and unlawful "reverse payment" settlement agreements.

Represented a leading French chemical manufacturer in connection with antitrust claims based on allegedly restrictive supply agreements with a pharmaceutical manufacturer.

Represented a generic pharmaceutical manufacturer against allegations of price-fixing, in what some commentators have called the largest price-fixing case in the history of the United States.

Represented Pfizer in a case involving allegations of exclusive dealing and unfair bundling practices, among other allegations.

Represented a leading cybersecurity firm against allegations of a group boycott brought by a cybersecurity testing company.

Represented Allergan, a leading pharmaceutical manufacturer, in monopolization and restraint of trade cases involving allegations of unlawful "reverse payment" settlements as well as claims of "product hopping" and fraud on the United States Patent and Trademark Office.

Represented a leading pharmaceutical manufacturer in a case involving the introduction of new pharmaceutical products, which some have dubbed "product hopping."

Represented Allergan, a leading pharmaceutical manufacturer, in a case involving alleged "product hopping"; obtained First Circuit review of the class certification and ultimately achieved de-certification of the class.

Represented a leading vaccines manufacturer in a case involving bundling practices in the vaccines market.

Represented OPEC in a putative class action alleging price fixing of petroleum products.

Represented a leading pharmaceutical manufacturer in industry-wide litigation brought by a secondary wholesaler, alleging violations of the Sherman Act. The action involved many of the largest pharmaceutical manufacturers and wholesalers.

Represented a leading credit reporting agency in an action brought by the dominant provider of consumer credit risk scoring services against the three major US credit reporting agencies. The action included claims under the antitrust, trademark and false advertising laws. White & Case obtained dismissal of most of the plaintiff's claims at summary judgment, and a jury verdict completely in our client's favor on the remaining claims.

Represented a major pharmaceuticals manufacturer in a monopolization case involving allegations of fraud on the United States Patent and Trademark Office and obtained successful resolution on the eve of trial.

Represented a major pharmaceutical manufacturer in restraint of trade and monopolization claims arising from a competitor's exclusive supply agreement.